research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
Search
for
Sort by
Research
690-720 / 1000+ results 
research 112 Post-Finasteride Syndrome – Outcomes of FDA Database
research Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
EGFR-TKIs can cause significant skin, nail, and organ side effects.
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
PRP treatments for hair loss need standard protocols to be reliable.
research Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Finasteride is most linked to drug-induced erectile dysfunction.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
Finasteride increases risk of sleep apnea and insomnia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Is finasteride intake associated with penile curvature/peyronie’s disease? Assessment of both the food and drug administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
research A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection
Drug advertising has greatly increased, changing consumer behavior and raising concerns about its influence on healthcare and patient protection.
research Alopecia Areata: An Updated Review for 2023
Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Expert System for Hair Loss Diagnosis and Treatment
Minoxidil and Propecia are the only FDA-approved hair growth drugs, but concerns about side effects lead people to explore herbal alternatives.
research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
research Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism
Hair loss treatments include medications and new methods like low-level light therapy, which may work by boosting cell activity and blood flow.
research Nanotechnology-Based Cosmetics for Hair Care
Nanotechnology improves hair care products by enhancing ingredient stability, targeting treatment, and reducing side effects, but more research on its toxicity is needed.
research A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention
Scalp cooling can help prevent chemotherapy-induced hair loss with a 50-90% success rate and is safe for patients.
research Photobiomodulation devices for hair regrowth and wound healing: a therapy full of promise but a literature full of confusion
Photobiomodulation may help with hair growth and wound healing, but research is inconsistent and needs better quality studies.
research Robotic Hair Restoration
The ARTAS robotic system for hair restoration is efficient with fewer cuts than manual methods, but it's limited to certain hair types and can still leave scars.
research ANDROGENETIC ALOPECIA
Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.